New active surveillance parameters allow for more individualized patient care

April 26, 2009

LINTHICUM, MD, April 26, 2009-Active surveillance may be a viable option for some men, but reclassification of disease risk over time is imperative to ensure outcomes, according to researchers in Toronto, who will present these criteria during the 104th Annual Scientific Meeting of the American Urological Association (AUA). Active surveillance can offer prostate cancer patients the benefit of an individualized approach based on reclassification of the risk of disease progression over time. Active surveillance using carefully defined criteria can decrease the burden of therapy in patients with slow growing disease, while providing definitive therapy for those with more aggressive disease.

Active surveillance is typically offered to men with slow-growing prostate cancer that may not progress within their lifetime. In other words, the cancer is not likely to be fatal and treatment might cause unnecessary adverse effects. Patients on active surveillance undergo periodic screenings to determine disease progression or risk.

This abstract represents data from the second phase of this study, which was initiated in 1995. Since then, researchers have studied 453 active surveillance candidates to determine the best intervention parameters (at what point physicians should intervene and offer more aggressive treatment options). Study results show that patients who experience a prostate-specific antigen (PSA) doubling time of less than three years or a pathologic progression to Gleason 4+3 are at a higher risk for disease progression and require more aggressive treatment.

In the initial stage of the study, researchers offered active surveillance to prostate cancer patients with favorable risk parameters (Gleason less than or equal to 6, and PSA less than or equal to 10) as an alternative to radical treatment. Patients were followed with serial PSA testing and periodic biopsy. Intervention was offered based on PSA kinetics or grade progression. In 2000, the study was restricted to favorable risk disease. Definitive intervention was offered to those patients with a PSA doubling time of less than three years, Gleason score progression (to 4+3 or greater) or unequivocal clinical progression.

Of the 453 patients on the program, the median age is currently 70, the median follow-up is 7.2 years, the overall survival is 83 percent and the prostate cancer survival is 99 percent. Five of the 453 patients have died of prostate cancer; 35 percent have been reclassified as higher risk and offered definitive therapy. The most common indications for treatment were a PSA doubling time of less than three years or Gleason upgrading. Of the 137 patients treated surgically, the PSA failure rate (rising PSA) was 52 percent. Patients with biochemical failure after radical therapy constitute 15 percent of the overall study group. The ratio of non-prostate cancer to prostate cancer mortality was 16.

"In terms of evaluating the outcome from any prostate cancer therapy or watchful waiting protocol, the duration of observation is critical. Although 7.2 years of follow-up, as noted here, seems long, many investigators would be careful with any conclusions until the follow-up time exceeded 10 years," said Kevin T. McVary, MD, an AUA spokesman. "Regardless, watchful waiting is an appropriate and commonly practiced care for selected men with prostate cancer."
-end-
NOTE TO REPORTERS: Experts are available to discuss these studies outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail Lacey Dean at LDean@AUAnet.org.

Klotz, L; Nam, R; Lam, A; Mamedov, A; Loblaw, A. Clinical results of long term follow-up of a large active-surveillance cohort. J Urol, suppl. 2009: 181, 4, abstract 460.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

American Urological Association

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.